Clinical trials: Vaccine Effectiveness Against COVID-19
Covid19
Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults
This phase I study is designed as double-blinded, randomised, placebo controlled, three-armed study composed of two different dose arms of protective adjuvanted inactivated vaccine against SARS-CoV-2 in dose escalations (first…
- Trial name
- COVID-19 (NCT04866069)
- Testing
- SARS-CoV-2 vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Osman ERGANIS, PhD, Prof
COVID-19
Safety and Efficacy of Intranasal Administration of Avacc 10 Vaccine Against COVID-19 in Healthy Volunteers
This study is a Phase I, first-in-human (FIH), double-blind, placebo- and OMV-controlled study of Avacc 10 in healthy adult male and female subjects to investigate the safety, tolerability, and immunogenicity of intranasally…
- Trial name
- ITV2002 (NCT05604690)
- Testing
- Avacc 10, Outer Membrane Vesicles (OMV) : OMV alone in vehicle
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Intravacc B.V.
COVID-19
Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19
The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of the COVID-19 vaccine, mRNA-1273, in adults aged 50-64 years without known risk factors for severe COVID-19 infection.
- Trial name
- DAN-COVID (NCT07279766)
- Testing
- mRNA-1273 (Moderna COVID-19 vaccine)
- Where
- 2 sites in Denmark
- Volunteers
- 41,060 people, healthy volunteers welcome
- Sponsor
- Tor Biering-Sørensen
Covid19
Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19
This study is a phase III clinical trial to evaluate efficacy, reactogenicity and safety of the vaccine Ad5-nCoV compared with placebo in volunteers at the age from 18 to 85 years，with the randomized, double-blind design
- Trial name
- NCT04540419
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- 7 sites in Russia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- NPO Petrovax
COVID-19, Sars-CoV-2 Infection
Phase 3 Booster Vaccination Against COVID-19
The inactivated Booster Phase 3 study aims to determine the efficacy, safety, and immunogenicity of inactivated COVID-19 vaccines in subjects with a minimum of 90 days and a maximum of 270 days after the second dose of CoronaVac…
- Trial name
- NCT05077176
- Testing
- CoronaVac, Turkovac
- Where
- 41 sites in Turkey (Türkiye)
- Volunteers
- 4,340 people, healthy volunteers welcome
- Sponsor
- Health Institutes of Turkey
Covid19, Vaccines
Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults
The study will evaluate the efficacy, safety, and immunogenicity of two vaccination schedules of an inactivated vaccine against SARS-CoV-2 infection in adults.
- Trial name
- CoronaVac3CL (NCT04651790)
- Testing
- SARS-CoV-2 inactivated vaccine
- Where
- Chile
- Volunteers
- 2,300 people, healthy volunteers welcome
- Sponsor
- Pontificia Universidad Catolica de Chile
Coronavirus
Investigating a Vaccine Against COVID-19
A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in healthy UK volunteers.
- Trial name
- NCT04400838
- Testing
- ChAdOx1 nCoV-19 (Abs 260), MenACWY vaccine, ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost
- Where
- 20 sites in United Kingdom
- Volunteers
- 10,811 people, healthy volunteers welcome
- Sponsor
- University of Oxford
COVID-19, Vaccine Adverse Reaction
Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
The objective of this observational case-crossover study is to evaluate the effectiveness, safety and immunogenicity of the second booster dose in the elderly.
- Conditions
- COVID-19, Vaccine Adverse Reaction, Vaccine-Preventable Diseases
- Trial name
- Plus_Booster (NCT05283902)
- Testing
- ChAdOx1 nCoV-19 or Comirnaty or Janssen COVID-19 Vaccine
- Where
- Brazil
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Federal University of Espirito Santo
Immunogenicity, Safety
mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs
Primary#Objectives #Immunogenicity:To demonstrate the non-inferiority of binding antibody response in terms of geometric mean titers (GMT) of mRNA vaccine compare with mRNA COVID-19 vaccine(Pfizer) 14 days post dose.
- Conditions
- Immunogenicity, Safety, Efficacy
- Trial name
- NCT05686161
- Testing
- SW-BIC-213;SARS-Cov-2., Sinopharm (BIBP);SARS-Cov-2., Pfizer(BNT162b2);SARS-Cov-2.
- Where
- Laos
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Stemirna Therapeutics
COVID-19, Sars-CoV-2 Infection
Booster Vaccination Against COVID-19
A booster dose of vaccine (Turkovac or CoronaVac) will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
- Trial name
- NCT04979949
- Testing
- CoronaVac, Turkovac
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- Health Institutes of Turkey
Immunogenicity, Safety
A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2
Primary Immunogenicity Objective：Cohort 1: GMTs of SARS-CoV-2 Omicron and related strain neutralizing antibody levels for SWIM816.Cohort 2: To demonstrate the non- inferiority of neutralizing antibody response in terms of…
- Trial name
- NCT05911087
- Testing
- Phase II:SWIM816;SARS-Cov-2;, Phase II:SW-BIC-213;SARS-Cov-2;, PhaseIII:SWIM816;SARS-Cov-2;
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Stemirna Therapeutics
COVID-19
Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC]
PRIBIVAC will assess a heterologous prime-boost-boost strategy in comparison with a homologous regimen in order to compare short and long-term immunogenicity of different COVID-19 vaccine combinations against the ancestral…
- Trial name
- PRIBIVAC (NCT05142319)
- Testing
- Homologous mRNA booster vaccine, Heterologous mRNA booster vaccine, COVAXIN
- Where
- Singapore
- Volunteers
- 326 people, healthy volunteers welcome
- Sponsor
- Tan Tock Seng Hospital
Kidney Diseases, Kidney Transplant; Complications
Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.
Prospective observational trial to assess immunological safety (anti-HLA antibodies, donor-derived cell-free DNA) and immunological effectiveness (anti-SARS-CoV-2 IgG) of the first booster dose of SARS-CoV-2 mRNA vaccines in…
- Conditions
- Kidney Diseases, Kidney Transplant; Complications, COVID-19, Vaccine Adverse Reaction
- Trial name
- NCT05483725
- Testing
- Booster dose of mRNA vaccine
- Where
- Czechia
- Volunteers
- 108 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Covid19
Efficacy, Safety, and Immunogenicity of Vaccine Reimmunization With a Third Homologous Versus Heterologous Dose Against COVID-19 in Patients Undergoing Solid Organ Transplantation.
Patients undergoing solid organ transplantation randomly selected from those who have received two doses of Spikevax (Moderna) vaccine, provided that a minimum of 8 weeks have elapsed from the second dose to the time of the start…
- Trial name
- REIN-TX (NCT05048940)
- Testing
- Janssen vaccine, Spikevax (Moderna) vaccine
- Where
- Spain
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Chronic Liver Disease, Hepatic Carcinoma
A Study to Evaluate Vaccines Against COVID-19 in the Real World
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (COVID-19) have afflicted tens of millions of people in a worldwide pandemic.
- Trial name
- NCT04775056
- Where
- Hong Kong
- Volunteers
- healthy volunteers welcome
- Sponsor
- Humanity & Health Medical Group Limited
COVID-19
Efficacy, Immunogenicity and Safety of Inactivated Vaccine (Coronavac) Against SARS-COV2 in Children and Adolescents
To evaluate the efficacy and safety of vaccinating children and adolescents, aged 3 to 17 years, with a two-dose schedule of the inactivated vaccine (Coronavac) against SARS-Cov-2.
- Trial name
- Curumim (NCT05225285)
- Testing
- Inactivated Coronavac/Butantan vaccine, BNT162b2 (Pfizer)
- Where
- Brazil
- Volunteers
- 1,120 people, healthy volunteers welcome
- Sponsor
- Federal University of Espirito Santo
COVID-19, SARS-CoV-2
A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above
Approximately 28,000 subjects will be enrolled in this trial. Eligible subjects will be stratified by age (<60 years of age and ≥60 years of age, the proportion of elderly people ≥60 years old is planned to be ≥25%) and randomly…
- Trial name
- NCT04847102
- Testing
- SARS-CoV-2 mRNA Vaccine
- Where
- 12 sites in Indonesia, Mexico
- Volunteers
- 28,000 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
Covid19 Prevention
Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19
Randomized, double-blind (blinded for the trial subject and the study physician), placebo controlled, multi-center clinical trial in parallel assignment of efficacy, immunogenicity, and safety of the Gam-COVID-Vac combined vector…
- Trial name
- RESIST (NCT04530396)
- Testing
- Gam-COVID-Vac
- Where
- 23 sites in Russia
- Volunteers
- 33,758 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
This is a Phase 2/3, randomized, placebo-controlled, multi-center trial to evaluate the safety, immunogenicity and efficacy of INO-4800 administered by intradermal (ID) injection followed by electroporation (EP) using CELLECTRA®…
- Conditions
- Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19 Disease
- Trial name
- NCT04642638
- Testing
- INO-4800, CELLECTRA® 2000
- Where
- 27 sites in United States, Colombia and 1 more
- Volunteers
- 1,307 people, healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
COVID-19, Vaccine-Preventable Diseases
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
The purpose of this research study is to find out how well two different 2023-2024 updated COVID-19 vaccines protect people from COVID-19 (the disease caused by the SARS-CoV-2 virus), and to determine if getting a 2023-2024…
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection
- Trial name
- BEEHIVE (NCT06065176)
- Testing
- Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
- Where
- United States
- Volunteers
- 1,188 people, healthy volunteers welcome
- Sponsor
- Sarang K. Yoon, DO, MOH